[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Al-Barrag A, Al-Shaer M, Al-Matary N, Al-Hamdani M: 5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea. Clin Ophthalmol; 2010;4:801-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea.
  • OBJECTIVE: To evaluate the efficacy and risks of complications of pulse dosing of topical 5-fluorouracil (5-FU) in the treatment of corneal intraepithelial neoplasia (CIN), and conjunctival squamous cell carcinoma (SCC).
  • PARTICIPANTS: Fifteen patients with histological evidence CIN or SCC of the conjunctiva and cornea were identified by tumor biopsy.
  • Treatment cycles were defined as four times per day for 4 days using the medication followed by 30 days without medication.
  • The number of initial treatment was six cycles.
  • Additional chemotherapy was given after the initial treatment cycles, only for one case.
  • CONCLUSIONS: Adjuvant 1% topical 5-FU appears to be effective in the prevention of recurrence of conjunctival or corneal CIN and SCC after excision biopsy.
  • It is well-tolerated and an effective method of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • [Cites] Cornea. 2009 Aug;28(7):821-4 [19574900.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Surv Ophthalmol. 2004 Jan-Feb;49(1):3-24 [14711437.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1747-54 [15350332.001]
  • [Cites] Am J Ophthalmol. 1989 Apr 15;107(4):337-40 [2929703.001]
  • [Cites] Doc Ophthalmol. 1986 Dec 30;64(1):31-42 [3582100.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1985 Apr;26(4):580-3 [3980172.001]
  • [Cites] Am J Ophthalmol. 1984 May;97(5):547-59 [6720832.001]
  • [Cites] Am J Ophthalmol. 1983 Mar;95(3):359-63 [6829682.001]
  • [Cites] Surv Ophthalmol. 1995 May-Jun;39(6):429-50 [7660300.001]
  • [Cites] Arch Ophthalmol. 1994 Sep;112(9):1145-6 [8085957.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [Cites] Br J Ophthalmol. 1993 Nov;77(11):751-3 [8280698.001]
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Ophthalmology. 1997 Mar;104(3):485-92 [9082277.001]
  • [Cites] Ophthalmology. 1995 Sep;102(9):1338-44 [9097771.001]
  • [Cites] Arch Ophthalmol. 1997 Jun;115(6):808-15 [9194740.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Arch Ophthalmol. 1997 Dec;115(12):1600-1 [9400803.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Trans Am Ophthalmol Soc. 1976;74:154-71 [325854.001]
  • [Cites] Ophthalmologica. 1979;178(4):198-203 [481865.001]
  • [Cites] Am J Ophthalmol. 1976 Feb;81(2):198-206 [766640.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):381-3 [9439364.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Cornea. 1999 Jan;18(1):59-62 [9894938.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Arch Ophthalmol. 1999 Apr;117(4):544-5 [10206591.001]
  • [Cites] Br J Ophthalmol. 2000 Mar;84(3):268-72 [10684836.001]
  • [Cites] Ophthalmology. 2000 Dec;107(12):2190-5 [11097594.001]
  • [Cites] Ophthalmol Clin North Am. 2005 Mar;18(1):1-13, vii [15763187.001]
  • [Cites] Ophthalmology. 2002 Feb;109(2):249-52 [11825803.001]
  • (PMID = 20689797.001).
  • [ISSN] 1177-5483
  • [Journal-full-title] Clinical ophthalmology (Auckland, N.Z.)
  • [ISO-abbreviation] Clin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2915867
  • [Keywords] NOTNLM ; chemotherapy / fluorouracil / neoplasia / treatment cycles
  •  go-up   go-down


2. Huerva V, Mangues I: Treatment of conjunctival squamous neoplasias with interferon alpha 2ab. J Fr Ophtalmol; 2008 Mar;31(3):317-25
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of conjunctival squamous neoplasias with interferon alpha 2ab.
  • The classical approach to the treatment of squamous neoplasias of the ocular surface is based on surgical resection and cryotherapy.
  • Primary or adjuvant chemotherapy with mitomycin C (MMC) or 5-fluorouracil has been employed to treat these neoplasias, but severe side effects on the ocular surface have been described.
  • The experience in the treatment of conjunctiva-cornea intraepithelial neoplasia (CIN) with topical or intralesional INF alpha 2b is based on isolated cases or very short series.
  • The safety and effectiveness of INF alpha 2b in the treatment of primary and recurrent cases of CIN are described.
  • The absence of serious side effects after topical administration of INF alpha 2b leads to the recommendation of this modality of therapy for primary and recurrent cases of CIN.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Administration, Topical. Fluorouracil / therapeutic use. Humans. Mitomycin / therapeutic use. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404128.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 50SG953SK6 / Mitomycin; 99210-65-8 / interferon alfa-2b; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Nagaiah G, Stotler C, Orem J, Mwanda WO, Remick SC: Ocular surface squamous neoplasia in patients with HIV infection in sub-Saharan Africa. Curr Opin Oncol; 2010 Sep;22(5):437-42
HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular surface squamous neoplasia in patients with HIV infection in sub-Saharan Africa.
  • PURPOSE OF REVIEW: Ocular surface squamous neoplasia (OSSN) in sub-Saharan countries is an aggressive tumor that affects younger patients and appears to be increasing in incidence.
  • We undertook a PubMed search with the terms 'ocular surface squamous neoplasia', 'conjunctival carcinoma', 'HIV' and 'HPV', and 'sub-Saharan/Africa' to ascertain the scope of the problem and to review the available data, with an emphasis on publications of 2009 and the first quarter of 2010.
  • Treatment in Africa is primarily surgical.
  • Chemotherapy and antiviral agents have been used.
  • A diagnosis of OSSN in younger patients in sub-Saharan Africa should prompt HIV serotesting.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Eye Neoplasms / etiology. HIV Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2590-3 [18224690.001]
  • [Cites] Br J Ophthalmol. 2008 Apr;92(4):460-5 [18369059.001]
  • [Cites] Ophthalmology. 2008 Aug;115(8):1297-302, 1302.e1 [18294690.001]
  • [Cites] Clin Experiment Ophthalmol. 2008 Jul;36(5):422-5 [18939345.001]
  • [Cites] Int Ophthalmol. 2009 Oct;29(5):401-9 [18784902.001]
  • [Cites] Curr Eye Res. 2009 Aug;34(8):666-71 [19899994.001]
  • [Cites] Int J Cancer. 2010 Mar 1;126(5):1187-95 [19688826.001]
  • [Cites] Br J Cancer. 2010 Jan 19;102(2):262-7 [19997105.001]
  • [Cites] PLoS One. 2010;5(5):e10477 [20498858.001]
  • [Cites] Int J Cancer. 2010 Jul 15;127(2):427-32 [19908234.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):622-7 [11340563.001]
  • [Cites] Cornea. 2002 Mar;21(2):189-91 [11862092.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):301-8 [12177799.001]
  • [Cites] Eye (Lond). 2003 Mar;17(2):228-32 [12640411.001]
  • [Cites] Cent Afr J Med. 2003 Jan-Feb;49(1-2):1-4 [14562592.001]
  • [Cites] Arch Soc Esp Oftalmol. 2004 Aug;79(8):375-8 [15306963.001]
  • [Cites] Mutagenesis. 2004 Sep;19(5):399-401 [15388813.001]
  • [Cites] Arch Ophthalmol. 1992 Apr;110(4):525-7 [1562262.001]
  • [Cites] Am J Ophthalmol. 1994 Jan 15;117(1):97-102 [8291600.001]
  • [Cites] Lancet. 1995 Mar 18;345(8951):695-6 [7885126.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1450-1 [8676629.001]
  • [Cites] Br J Ophthalmol. 1996 Jun;80(6):503-8 [8759259.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):73-7 [9037556.001]
  • [Cites] Br J Ophthalmol. 1999 Feb;83(2):177-9 [10396194.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122(6):938-43 [15539387.001]
  • [Cites] Ophthalmologe. 2004 Oct;101(10):1011-6 [15185119.001]
  • [Cites] Ophthalmol Clin North Am. 2005 Mar;18(1):1-13, vii [15763187.001]
  • [Cites] Lancet. 2005 Sep 17-23;366(9490):991-8 [16168781.001]
  • [Cites] Cancer Lett. 2006 Jul 28;239(1):98-102 [16143449.001]
  • [Cites] East Afr Med J. 2006 May;83(5):267-70 [16866221.001]
  • [Cites] Eye (Lond). 2006 Aug;20(8):893-9 [16456599.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Cent Afr J Med. 2006 May-Jun;52(5-6):56-8 [18254456.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 Aug;5(3):120-5 [18627660.001]
  • (PMID = 20639761.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / D43 CA153707
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS634283; NLM/ PMC4209293
  •  go-up   go-down


Advertisement
4. Rahimi F, Alipour F, Ghazizadeh Hashemi H, Hashemian MN, Mehrdad R: Topical mitomycin-C for treatment of partially-excised ocular surface squamous neoplasia. Arch Iran Med; 2009 Jan;12(1):55-9
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin-C for treatment of partially-excised ocular surface squamous neoplasia.
  • BACKGROUND: This study was conducted to determine the treatment outcome of incompletely removed, histopathologically documented ocular surface squamous neoplasia with mitomycin-C.
  • METHODS: Through an interventional case series, 17 eyes of 17 patients presented with incompletely removed ocular surface squamous neoplasia were treated according to a protocol using two to three alternate seven-day courses of 0.04% mitomycin-C.
  • All patients had weekly follow-up visits to the end of the treatment course, then biweekly visits for three months, and monthly visits, thereafter.
  • Five patients (29.4%) experienced recurrence after the initial treatment; four of them responded to retreatment and were disease-free till the end of follow-up.
  • CONCLUSION: Point zero four percent (0.04%) mitomycin-C drop used as two to three alternate seven-day courses seems to be a safe and effective treatment for ocular surface squamous neoplasia.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Cornea. Eye Neoplasms / drug therapy. Mitomycin / administration & dosage. Ophthalmologic Surgical Procedures / methods. Sclera
  • [MeSH-minor] Adult. Aged. Conjunctival Neoplasms / drug therapy. Conjunctival Neoplasms / pathology. Conjunctival Neoplasms / surgery. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Ophthalmic Solutions. Prospective Studies. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19111031.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  •  go-up   go-down


5. Tunc M, Erbilen E: Topical cyclosporine-a combined with mitomycin C for conjunctival and corneal squamous cell carcinoma. Am J Ophthalmol; 2006 Oct;142(4):673-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical cyclosporine-a combined with mitomycin C for conjunctival and corneal squamous cell carcinoma.
  • PURPOSE: To determine the efficiency of topical cyclosporine-A (CSA) combined with mitomycin C (MMC) as an adjunctive treatment in diffuse conjunctival and corneal squamous cell carcinoma (CCSC).
  • METHODS: Two patients who had positive margins following surgical excision of CCSC were treated by topical CSA (0.05%) four times a day for 12 weeks, and topical MMC (0.01%) four times a day was combined with CSA at the second, fourth, and sixth weeks of the treatment.
  • CONCLUSIONS: As an adjunctive treatment, topical CSA (0.05%) combined with MMC (0.01%), may prevent tumor recurrence and provide excellent ocular surface healing in diffuse CCSC.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Cyclosporine / therapeutic use. Eye Neoplasms / drug therapy. Mitomycin / therapeutic use
  • [MeSH-minor] Administration, Topical. Aged. Antibiotics, Antineoplastic / therapeutic use. Drug Therapy, Combination. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011863.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; 50SG953SK6 / Mitomycin; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


6. Caujolle JP, Maschi C, Chauvel P, Herault J, Gastaud P: [Surgery and additional protontherapy for treatment of invasive and recurrent squamous cell carcinomas: technique and preliminary results]. J Fr Ophtalmol; 2009 Dec;32(10):707-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery and additional protontherapy for treatment of invasive and recurrent squamous cell carcinomas: technique and preliminary results].
  • [Transliterated title] Association chirurgie-protonthérapie dans le traitement des carcinomes invasifs et récidivants de la conjonctive: technique et résultats préliminaires.
  • INTRODUCTION: Invasive squamous cell carcinomas are uncommon neoplasias with high recurrence and mortality rates.
  • The improvement of tumoral control requires additional treatments such as cryotherapy, topical chemotherapy, and radiotherapy.
  • We present the technique and preliminary results of associating treatment with surgery and proton beam therapy for recurrent and invasive squamous cell carcinomas.
  • MATERIALS AND METHODS: From June 2001 to September 2008, 15 patients were treated in our ocular oncologic center for squamous cell carcinomas either with recurrences or with invaded resection margins.
  • The treatment combined new surgical resection with protontherapy.
  • Specific improvements in proton beam therapy have been made at the Nice Cyclotron to adapt the treatment to conjunctival tumors.
  • In 13 cases (86.8%), the bulbar and limbic conjunctiva was involved, in five of these cases the cornea was invaded, and the anterior chamber was involved in one case.
  • Moreover, proton beam therapy was performed more than 6 months after the initial treatment.
  • Exenteration and enucleation had to be performed to treat these recurrences 6 and 24 months after proton beam therapy.
  • No patients developed recurrences with additional proton beam therapy performed within 6 months after initial surgical resection.
  • CONCLUSION: Traditional adjuvant treatments often failed to control recurring and invasive squamous cell carcinomas.
  • The preliminary results of the present study suggest that proton beam therapy may be considered as a good alternative to traditional treatments with acceptable side effects.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Conjunctival Neoplasms / radiotherapy. Conjunctival Neoplasms / surgery. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Protons / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19942315.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


7. Karasawa K, Matsuda H, Tanaka A: Superficial keratectomy and topical mitomycin C as therapy for a corneal squamous cell carcinoma in a dog. J Small Anim Pract; 2008 Apr;49(4):208-10
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial keratectomy and topical mitomycin C as therapy for a corneal squamous cell carcinoma in a dog.
  • A 10-year-old female West Highland white terrier was presented with refractory hyperplastic keratitis of the left cornea of one month's duration.
  • At this time, a vascularised and rough lesion 5 mm in diameter was observed on the left cornea.
  • The corneal neoplasm was surgically removed and histologically diagnosed as a squamous cell carcinoma.
  • For two months after the surgery, 0.04 percent mitomycin C (MMC) eye drops were applied as adjuvant chemotherapy.
  • Primary corneal squamous cell carcinoma with no history of keratoconjunctivitis sicca is rare in dogs.
  • In the present report, surgical removal of the neoplasm was combined with the topical administration of the anticancer drug mitomycin C and a good prognosis was obtained.
  • The result indicates that the combination treatment used in this case may be an appropriate therapeutic choice for corneal squamous cell carcinoma in dogs.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Corneal Diseases / veterinary. Dog Diseases / drug therapy. Dog Diseases / surgery. Eye Neoplasms / veterinary
  • [MeSH-minor] Administration, Topical. Animals. Combined Modality Therapy. Corneal Surgery, Laser / methods. Corneal Surgery, Laser / veterinary. Dogs. Female. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725585.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin
  •  go-up   go-down


8. Tejani MA, Cohen RB, Mehra R: The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics; 2010 Aug 09;4:173-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer.
  • Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC) continues to be a source of significant morbidity and mortality worldwide.
  • Cetuximab, a monoclonal antibody against the EGFR, improves locoregional control and overall survival when used as a radiation sensitizer in patients with locoregionally advanced HNSCC undergoing definitive radiation therapy with curative intent.
  • Cetuximab is also active as monotherapy in patients whose cancer has progressed on platinum-containing therapy.
  • In the first-line setting for incurable HNSCC, cetuximab added to platinum-based chemotherapy significantly improves overall survival compared with standard chemotherapy alone.
  • In this review, we will discuss the mechanism of action, clinical data and common toxicities that pertain to the use of cetuximab in the treatment of advanced incurable HNSCC.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2008 Apr;13(4):365-73 [18394559.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3128-37 [18474878.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3138-46 [18474879.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2710-9 [18481809.001]
  • [Cites] Cornea. 2008 Jun;27(5):612-4 [18520515.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4284-91 [18594011.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1589-94 [18754871.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] Am J Clin Oncol. 2008 Aug;31(4):393-8 [18846001.001]
  • [Cites] Clin Adv Hematol Oncol. 2008 Oct;6(10):742-50 [18997665.001]
  • [Cites] J Infect Dis. 2009 May 1;199(9):1263-9 [19320589.001]
  • [Cites] Curr Opin Oncol. 2009 May;21(3):201-5 [19370803.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5851-9 [19584289.001]
  • [Cites] J Clin Oncol. 2010 Jan 1;28(1):8-14 [19917840.001]
  • [Cites] Radiat Res. 2003 Apr;159(4):439-52 [12643788.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8646-54 [16314626.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8288-94 [16322287.001]
  • [Cites] Eur J Cancer. 2006 Jan;42(1):109-11 [16324836.001]
  • [Cites] Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80 [16336752.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1072-8 [16505426.001]
  • [Cites] Prog Growth Factor Res. 1992;4(1):1-24 [1355372.001]
  • [Cites] Cell Regul. 1991 May;2(5):337-45 [1716463.001]
  • [Cites] Crit Rev Oncol Hematol. 1984;1(4):323-55 [6085038.001]
  • [Cites] Am J Otolaryngol. 1980 Aug;1(4):306-23 [6160777.001]
  • [Cites] J Otolaryngol. 1984 Apr;13(2):99-104 [6202878.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4637-42 [8402640.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1873-8 [8410112.001]
  • [Cites] Acta Oncol. 1998;37(3):285-9 [9677101.001]
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1311-8 [9815926.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1935-40 [10213503.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2166-74 [10873065.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):427-33 [11173137.001]
  • [Cites] Cornea. 2001 Jan;20(1):81-5 [11189010.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):535-42 [11208848.001]
  • [Cites] Exp Eye Res. 2001 May;72(5):511-7 [11311043.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1204-13 [11350885.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3234-43 [11432891.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):2958-70 [11595683.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S16-22 [11597400.001]
  • [Cites] Oral Oncol. 2002 Oct;38(7):627-40 [12167415.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7350-6 [12499279.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31574-83 [12771142.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1772-83 [14652239.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3639-50 [14666659.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30375-84 [15075331.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6166-73 [15342401.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6476-86 [15475435.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2760-5 [15701692.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):301-11 [15837620.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):575-89 [15950906.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1711-2 [15972283.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5568-77 [16009950.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):1871-5 [16158919.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9953-61 [16267020.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2866-72 [16717293.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4170-6 [16943533.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5064-73 [16951222.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Dec;6(8):691-710 [17168674.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Jan;136(1):98-103 [17210342.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1552-61 [17332301.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):553-8 [17372251.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2512-8 [17438112.001]
  • [Cites] Ann Oncol. 2007 May;18(5):961-2 [17442661.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2171-7 [17538161.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4291-9 [17634559.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3644-8 [17704414.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6555-60 [18006754.001]
  • [Cites] Radiother Oncol. 2008 Mar;86(3):383-90 [18037521.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1277-81 [18086972.001]
  • [Cites] Cancer Invest. 2008 Feb;26(1):96-103 [18181051.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1109-17 [18337601.001]
  • (PMID = 20714355.001).
  • [ISSN] 1177-5491
  • [Journal-full-title] Biologics : targets & therapy
  • [ISO-abbreviation] Biologics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2921255
  • [Keywords] NOTNLM ; cetuximab / epidermal growth factor receptor / squamous cell carcinoma of the head and neck
  •  go-up   go-down


9. Shields CL, Naseripour M, Shields JA: Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma. Am J Ophthalmol; 2002 May;133(5):601-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma.
  • PURPOSE: To evaluate the efficacy of topical mitomycin C for extensive recurrent conjunctival and corneal squamous cell carcinoma (SCC).
  • Ten patients (ten eyes) with extensive recurrent conjunctival and corneal SCC were studied.
  • The patients received topical mitomycin C 0.04% one drop four times daily in the eye with SCC.
  • Treatment cycles were defined as 1 week using medication followed by 1 week without medication.
  • Such treatment cycles were repeated until resolution of the conjunctival malignancy was clinically evident.
  • The main outcome measures were tumor response and medication-related complications.
  • Before referral, the patients had undergone a median of two previous conjunctival tumor resections revealing the diagnosis of in situ SCC in three cases and locally invasive SCC in six cases.
  • At presentation, the tumor involved the limbus and cornea in all ten eyes, forniceal conjunctiva in three eyes, and tarsal conjunctiva in one eye.
  • The extensive tumor affected a median of 10 clock hours of limbal conjunctiva and 10 clock hours of cornea, with corneal epithelial invasion for a median of 50% (range 20%-100%) of its surface.
  • Mitomycin C 0.04% four times daily was applied for a median of three cycles (range 1-4 cycles).
  • CONCLUSIONS: Based on this small series, topical mitomycin C 0.04% appears to be a safe and effective therapy for conjunctival or corneal SCC, even when there is extensive recurrent tumor.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Mitomycin / therapeutic use. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Drug Evaluation. Female. Humans. Male. Middle Aged. Prospective Studies. Safety. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Ophthalmol. 2003 Jan;135(1):122-3; author reply 123-4 [12504721.001]
  • (PMID = 11992855.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


10. Iovieno A, Lambiase A, Moretti C, Perrella E, Bonini S: Therapeutic effect of topical 5-fluorouracil in conjunctival squamous carcinoma is associated with changes in matrix metalloproteinases and tissue inhibitor of metalloproteinases expression. Cornea; 2009 Aug;28(7):821-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic effect of topical 5-fluorouracil in conjunctival squamous carcinoma is associated with changes in matrix metalloproteinases and tissue inhibitor of metalloproteinases expression.
  • PURPOSE: To evaluate matrix metalloproteinases (MMP)-2, MMP-9, and tissue inhibitor of metalloproteinase (TIMP)-1 expression in a case of conjunctival intraepithelial squamous cell carcinoma (SCC) treated with topical 5-fluorouracil (5-FU) chemotherapy.
  • Clinical resolution of the neoplasm obtained using topical 5-FU was accompanied by a reduction in the expression of MMP-2, MMP-9, and TIMP-1 in tears and dysplastic conjunctival epithelium.
  • CONCLUSIONS: In our case report, we have shown that gelatinase and TIMP-1 are unregulated in conjunctival SCC and can be monitored as a marker of response to topical chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Fluorouracil / therapeutic use. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Tissue Inhibitor of Metalloproteinase-1 / metabolism
  • [MeSH-minor] Administration, Topical. Aged. Biomarkers, Tumor / metabolism. Carcinoma in Situ / drug therapy. Carcinoma in Situ / enzymology. Humans. Male. Neoplasm Proteins / metabolism

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574900.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Barbazetto IA, Lee TC, Abramson DH: Treatment of conjunctival squamous cell carcinoma with photodynamic therapy. Am J Ophthalmol; 2004 Aug;138(2):183-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of conjunctival squamous cell carcinoma with photodynamic therapy.
  • PURPOSE: The aim of this study was to describe the clinical and angiographic response of squamous cell carcinoma (SCC) of the conjunctiva to treatment with photodynamic therapy (PDT).
  • Patients received one to three treatments of verteporfin (6 mg/m(2) body surface area, intravenously).
  • The mean follow-up time was 8.6 months (7 to 12 months).
  • Main outcome measurements were clinical and angiographic response and treatment-related side effects.
  • RESULTS: One week after treatment, angiographic occlusion of tumor vasculature and normal conjunctival vessels was observed in all patients.
  • Tumor regression was noted in all patients 1 month after treatment.
  • Two patients had complete regression (clinical and angiographic observation) after one or two treatments for the entire follow-up time.
  • One tumor involved large aspects of the conjunctiva and cornea.
  • PDT caused minimal temporary local irritation in two patients, and small conjunctival hemorrhages and mild transient chemosis in the three eyes directly after treatment.
  • CONCLUSION: The preliminary results of this study suggest that PDT may be a valuable addition to the treatment of patients with SCC of the conjunctiva.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Neovascularization, Pathologic / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Porphyrins / therapeutic use

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Ophthalmol. 2005 Apr;139(4):759-60; author reply 760 [15808212.001]
  • (PMID = 15289124.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


12. Prabhasawat P, Tarinvorakup P, Tesavibul N, Uiprasertkul M, Kosrirukvongs P, Booranapong W, Srivannaboon S: Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma. Cornea; 2005 May;24(4):443-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma.
  • PURPOSE: To demonstrate the efficacy of topical 0.002% mitomycin C (MMC) as an adjunctive and alternative treatment in primary and recurrent conjunctival-corneal intraepithelial neoplasia (CCIN) and squamous cell carcinoma (SCC).
  • All cases were treated with topical 0.002% MMC 4 times daily.
  • The tumor size pre- and post-treatment, clinical response, and ocular complications were evaluated.
  • Before MMC treatment, 6 eyes (85.7%) had recurrences after surgical excision.
  • MMC 0.002% 4 times daily was applied for a period of 5.4 +/- 4.4 weeks (range, 2-14).
  • Side effects of MMC therapy included ocular irritation, mild conjunctival hyperemia, and punctate keratopathy.
  • The mean follow-up time was 30.7 +/- 15 months (range, 2-52) with no evidence of clinical recurrence in any case.
  • CONCLUSIONS: Topical 0.002% MMC showed a favorable outcome as an adjunctive and alternative treatment of CCIN and SCC with regression of primary and recurrent tumors.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Mitomycin / administration & dosage
  • [MeSH-minor] Administration, Topical. Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829803.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


13. Khokhar S, Soni A, SinghSethi H, Sudan R, Sony P, Pangtey MS: Combined surgery, cryotherapy, and mitomycin-C for recurrent ocular surface squamous neoplasia. Cornea; 2002 Mar;21(2):189-91
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined surgery, cryotherapy, and mitomycin-C for recurrent ocular surface squamous neoplasia.
  • PURPOSE: To report the outcome of combined excision, cryotherapy, and antimetabolite treatment of recurrent ocular surface squamous neoplasia.
  • METHODS: The patients with recurrent ocular surface squamous neoplasia were treated by excision of lesion, cryotherapy of limbus, and conjunctival margin followed by 0.02% Mitomycin C application at the time of surgery.
  • RESULTS: A total of five eyes of five patients with recurrent ocular surface squamous neoplasia were treated by combined excision, cryotherapy, and Mitomycin C.
  • Histopathologic diagnosis included invasive squamous cell carcinoma in four cases and squamous dysplasia in one case.
  • CONCLUSION: Combining excision with cryotherapy and Mitomycin C application at the time of surgery is a very effective therapy for recurrent ocular surface squamous neoplasia.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / therapy. Cryosurgery. Eye Neoplasms / therapy. Mitomycin / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Conjunctival Neoplasms / therapy. Corneal Diseases / therapy. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11862092.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


14. Zaki AA, Farid SF: Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up. Cornea; 2009 Oct;28(9):986-8
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up.
  • PURPOSE: The aim of this work is to report the long-term results of using immunotherapy for the management of cornea and conjunctiva intraepithelial neoplasia and squamous cell carcinoma after surgical excision of the neoplasm.
  • METHODS: Ten eyes of 10 patients with cornea and conjunctiva intraepithelial neoplasia or squamous cell carcinoma had wide surgical excisions of the neoplasm after evaluation of the level of corneal involvement using ultrasound biomicroscopy.
  • All eyes received topical cyclosporine A (0.05%) and topical mitomycin C (0.01%) 4 times daily for 12 weeks after surgery.
  • Epithelial toxicity (punctate keratopathy) occurred in 3 eyes, ocular irritation and mild conjunctival hyperemia in 5 eyes, and lid toxicity in 2 cases during the treatment with mitomycin C.
  • There were no serious complications that necessitated stopping the treatment.
  • CONCLUSION: During a 2-year follow-up period, the use of topical cyclosporine A (0.05%) combined with mitomycin C (0.01%) as an adjunctive treatment after surgical excision in cornea and conjunctiva intraepithelial neoplasia and squamous cell carcinoma was found to prevent tumor recurrence, especially in extensive lesions, when surgical excision cannot ensure a tumor-free margin.
  • [MeSH-major] Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Conjunctival Neoplasms / therapy. Corneal Diseases / therapy. Eye Neoplasms / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclosporine / administration & dosage. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Mitomycin / administration & dosage. Neoplasm Invasiveness. Ophthalmologic Surgical Procedures. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cornea. 2012 Apr;31(4):465 [22314824.001]
  • [CommentIn] Cornea. 2011 Apr;30(4):486; author reply 486-7 [21107255.001]
  • (PMID = 19724215.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


15. Kemp EG, Harnett AN, Chatterjee S: Preoperative topical and intraoperative local mitomycin C adjuvant therapy in the management of ocular surface neoplasias. Br J Ophthalmol; 2002 Jan;86(1):31-4
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative topical and intraoperative local mitomycin C adjuvant therapy in the management of ocular surface neoplasias.
  • AIMS: To demonstrate the efficacy of mitomycin C as adjuvant therapy preoperatively and intraoperatively in the management of recurrent or diffuse ocular surface neoplasias.
  • METHODS: The case notes of 11 patients receiving mitomycin C adjuvant therapy as 0.04% eye drops four times a day in two weekly courses preoperatively and/or a single intraoperative application of 0.4 mg/ml of mitomycin C were reviewed.
  • The histopathology included conjunctival primary acquired melanosis, conjunctival melanomas, sebaceous cell carcinomas with conjunctival intraepithelial spread, and conjunctival intraepithelial squamous neoplasias.
  • RESULTS: All cases showed a favourable response to mitomycin C adjuvant therapy with regression in size or retardation of a rapid growth pattern and no serious sequelae.
  • CONCLUSION: In this series, mitomycin C adjuvant therapy of recurrent or diffuse ocular surface neoplasias was well tolerated and showed favourable clinical results.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma / drug therapy. Eye Neoplasms / drug therapy. Melanoma / drug therapy. Mitomycin / administration & dosage
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / methods. Female. Follow-Up Studies. Humans. Intraoperative Care / methods. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Ophthalmic Solutions / administration & dosage. Preoperative Care / methods

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ophthalmol. 1999 Nov;128(5):638-40 [10577537.001]
  • [Cites] Br J Ophthalmol. 1998 May;82(5):476-9 [9713051.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Trans Am Ophthalmol Soc. 1976;74:154-71 [325854.001]
  • [Cites] Am J Ophthalmol. 1979 Jan;87(1):84-6 [434057.001]
  • [Cites] Trans Am Ophthalmol Soc. 1980;78:290-300 [7257061.001]
  • [Cites] Am J Ophthalmol. 1983 Mar;95(3):359-63 [6829682.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1990 Oct;31(10):2136-44 [2211010.001]
  • [Cites] Ophthalmology. 1990 Sep;97(9):1204-10 [2122349.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):317-21 [2023752.001]
  • [Cites] Arch Ophthalmol. 1991 Aug;109(8):1141-6 [1907822.001]
  • [Cites] Trans Am Ophthalmol Soc. 1991;89:285-98; discussion 298-301 [1808811.001]
  • [Cites] Ophthalmology. 1992 Dec;99(12):1809-14 [1480395.001]
  • [Cites] Ophthalmology. 1997 May;104(5):844-8 [9160032.001]
  • [Cites] Ophthalmic Surg Lasers. 1997 Aug;28(8):662-9 [9268998.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Cornea. 2000 Jan;19(1):1-6 [10631999.001]
  • (PMID = 11801499.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  • [Other-IDs] NLM/ PMC1770962
  •  go-up   go-down


16. Siganos CS, Kozobolis VP, Christodoulakis EV: The intraoperative use of mitomycin-C in excision of ocular surface neoplasia with or without limbal autograft transplantation. Cornea; 2002 Jan;21(1):12-6
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Seven patients (eight eyes), three men and four women, aged 56 to 87 years (mean, 73.8 years), with lesions suspicious for corneal or conjunctival neoplasia, were operated on between October 1998 and March 2000.
  • Histopathologic study showed four cases of squamous cell carcinoma, one case of carcinoma in situ, two cases of dysplasia, and one case of actinic keratosis.
  • Of the eight eyes, no clinical recurrence of the lesion occurred in seven eyes, whereas one eye with squamous cell carcinoma showed mild recurrence 5 months after surgery and was successfully treated with topical mitomycin-C.
  • CONCLUSION: The excision of conjunctival and corneal epithelial neoplasia combined with the intraoperative use of mitomycin-C seems to reduce the recurrence rate.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Conjunctival Neoplasms / surgery. Corneal Diseases / surgery. Epithelial Cells / transplantation. Eye Neoplasms / surgery. Limbus Corneae / cytology. Mitomycin / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma in Situ / drug therapy. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Cell Transplantation. Female. Humans. Intraoperative Care. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cornea. 2002 Nov;21(8):840-1; author reply 841-2 [12410051.001]
  • [ErratumIn] Cornea. 2003 Mar;22(2):189.
  • (PMID = 11805500.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


17. Verma V, Shen D, Sieving PC, Chan CC: The role of infectious agents in the etiology of ocular adnexal neoplasia. Surv Ophthalmol; 2008 Jul-Aug;53(4):312-31
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By elucidating the mechanisms by which infectious agents contribute to oncogenesis, the management, treatment, and prevention of these neoplasms may one day parallel what is already in place for cancers such as cervical cancer, hepatocellular carcinoma, gastric mucosa-associated lymphoid tissue lymphoma and gastric adenocarcinoma.
  • Antibiotic treatment and vaccines against infectious agents may herald a future with a curtailed role for traditional therapies of surgery, radiation, and chemotherapy.
  • This review discusses the pathogenetic role of several microorganisms in different ocular adnexal malignancies, including human papilloma virus in conjunctival papilloma and squamous cell carcinoma, human immunodeficiency virus in conjunctival squamous carcinoma, Kaposi sarcoma-associated herpes virus or human herpes simplex virus-8 (KSHV/HHV-8) in conjunctival Kaposi sarcoma, Helicobacter pylori (H. pylori,), Chlamydia, and hepatitis C virus in ocular adnexal mucosa-associated lymphoid tissue lymphomas.
  • [MeSH-minor] Alphapapillomavirus / isolation & purification. Alphapapillomavirus / physiology. Carcinoma, Squamous Cell / virology. Chlamydophila psittaci / isolation & purification. Chlamydophila psittaci / physiology. Conjunctival Neoplasms / microbiology. Conjunctival Neoplasms / virology. Eyelid Neoplasms / microbiology. Eyelid Neoplasms / virology. HIV-1 / isolation & purification. HIV-1 / physiology. Helicobacter pylori / isolation & purification. Helicobacter pylori / physiology. Hepacivirus / isolation & purification. Hepacivirus / physiology. Herpesvirus 8, Human / isolation & purification. Herpesvirus 8, Human / physiology. Humans. Lacrimal Apparatus Diseases / microbiology. Lacrimal Apparatus Diseases / virology. Lymphoma, B-Cell, Marginal Zone / virology. Orbital Neoplasms / microbiology. Orbital Neoplasms / virology. Sarcoma, Kaposi / virology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Ophthalmol Scand. 2000 Dec;78(6):663-6 [11167228.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1218-23 [11158620.001]
  • [Cites] Ophthalmology. 2001 Mar;108(3):559-62 [11237911.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]
  • [Cites] Ophthalmology. 2001 May;108(5):979-84 [11320031.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):301-8 [12177799.001]
  • [Cites] Cornea. 2002 Nov;21(8):838-9 [12410049.001]
  • [Cites] Leuk Lymphoma. 2002 Oct;43(10):1975-7 [12481895.001]
  • [Cites] Cornea. 2003 Jan;22(1):1-4 [12502938.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):489-90 [12571255.001]
  • [Cites] Arch Ophthalmol. 2003 Feb;121(2):280-2 [12583801.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):159-69 [12584163.001]
  • [Cites] Ophthalmologe. 2003 Feb;100(2):142-4 [12589459.001]
  • [Cites] Cornea. 2003 Mar;22(2):135-7 [12605048.001]
  • [Cites] Acta Ophthalmol Scand. 2003 Apr;81(2):193-6 [12752062.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3371-85 [12776188.001]
  • [Cites] Arch Soc Esp Oftalmol. 2003 May;78(5):265-71 [12789630.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):57-65 [12807947.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]
  • [Cites] Acta Ophthalmol Scand. 2003 Aug;81(4):411-3 [12859274.001]
  • [Cites] Arch Ophthalmol. 2003 Jul;121(7):1052-3 [12860816.001]
  • [Cites] J Med Microbiol. 2003 Aug;52(Pt 8):721-6 [12867569.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):865-71 [12910532.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1341-5 [12954572.001]
  • [Cites] Cent Afr J Med. 2003 Jan-Feb;49(1-2):1-4 [14562592.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1747-54 [15350332.001]
  • [Cites] Histol Histopathol. 2004 Oct;19(4):1219-26 [15375765.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] N Engl J Med. 1978 Nov 30;299(22):1215-20 [309554.001]
  • [Cites] Am J Ophthalmol. 1982 Apr;93(4):393-402 [6280503.001]
  • [Cites] Ann Ophthalmol. 1982 May;14(5):497-9 [7114684.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Am J Ophthalmol. 1983 Nov;96(5):670-4 [6314814.001]
  • [Cites] Ophthalmology. 1984 Sep;91(9):1092-9 [6093020.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1985;223(3):164-7 [2993107.001]
  • [Cites] Anticancer Res. 1985 Sep-Oct;5(5):485-98 [3904595.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • [Cites] Arch Ophthalmol. 1986 Dec;104(12):1801-5 [3024607.001]
  • [Cites] Arch Ophthalmol. 1986 Dec;104(12):1814-5 [3024608.001]
  • [Cites] Am J Ophthalmol. 1987 Mar 15;103(3 Pt 1):294-301 [3030111.001]
  • [Cites] J Natl Cancer Inst. 1987 Oct;79(4):671-7 [2821311.001]
  • [Cites] Hum Pathol. 1987 Nov;18(11):1115-9 [2824322.001]
  • [Cites] Hum Pathol. 1988 Nov;19(11):1315-26 [3141260.001]
  • [Cites] N Engl J Med. 1989 Jun 1;320(22):1442-6 [2541337.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):123-8 [1967430.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27 [8548526.001]
  • [Cites] J Clin Pathol. 1995 Dec;48(12):1106-10 [8567996.001]
  • [Cites] Ophthalmology. 1996 Apr;103(4):631-5 [8618763.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1450-1 [8676629.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):2009-16 [8669485.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Br J Ophthalmol. 1999 Jun;83(6):742-7 [10340987.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1725-33 [10528022.001]
  • [Cites] Sex Transm Infect. 1999 Oct;75(5):317-9 [10616355.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2583-8 [10630528.001]
  • [Cites] J Clin Pathol. 1999 Aug;52(8):569-73 [10645225.001]
  • [Cites] Br J Ophthalmol. 2000 Mar;84(3):268-72 [10684836.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 May;41(6):1270-9 [10798640.001]
  • [Cites] J Immunol. 2000 May 15;164(10):5522-9 [10799921.001]
  • [Cites] Nat Med. 2000 May;6(5):536-42 [10802709.001]
  • [Cites] J Biomed Sci. 2000 Sep-Oct;7(5):341-56 [10971133.001]
  • [Cites] J Med Virol. 2000 Oct;62(2):251-8 [11002256.001]
  • [Cites] Arch Ophthalmol. 1997 Nov;115(11):1464-6 [9366682.001]
  • [Cites] Gastroenterology. 1997 Dec;113(6):1848-57 [9394724.001]
  • [Cites] Gastroenterology. 1997 Dec;113(6 Suppl):S61-4 [9394762.001]
  • [Cites] Ophthalmology. 1998 Jan;105(1):185-90 [9442797.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Feb;157(2):458-63 [9476858.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2290-5 [9482878.001]
  • [Cites] Br J Ophthalmol. 1997 Nov;81(11):1019-20 [9505833.001]
  • [Cites] Annu Rev Med. 1998;49:289-99 [9509264.001]
  • [Cites] N Engl J Med. 1998 Apr 2;338(14):948-54 [9521982.001]
  • [Cites] Sex Transm Infect. 1998 Feb;74(1):32-4 [9634298.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):65-71 [9709306.001]
  • [Cites] Bull Soc Belge Ophtalmol. 1998;268:135-41 [9810095.001]
  • [Cites] AIDS. 1998 Oct 22;12(15):2067-72 [9814876.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Mar;40(3):555-62 [10067957.001]
  • [Cites] Gastroenterology. 1999 Apr;116(4):823-30 [10092304.001]
  • [Cites] Ophthalmology. 1999 Apr;106(4):757-60 [10201599.001]
  • [Cites] Br J Ophthalmol. 1999 Jan;83(1):98-103 [10209445.001]
  • [Cites] J Reprod Immunol. 1998 Dec;41(1-2):149-60 [10213307.001]
  • [Cites] J Vet Intern Med. 1999 May-Jun;13(3):153-62 [10357102.001]
  • [Cites] Cornea. 1999 Jul;18(4):495-7 [10422866.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] BMJ. 1999 Aug 21;319(7208):505-8 [10454408.001]
  • [Cites] Cornea. 2001 May;20(4):427-9 [11333335.001]
  • [Cites] Br J Ophthalmol. 2001 Jul;85(7):785-7 [11423448.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1251-69 [11423257.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):641-9 [11454995.001]
  • [Cites] Dermatology. 2001;203(1):19-23 [11549794.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2450-7 [11581182.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):958-65 [11583749.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;941:69-85 [11594584.001]
  • [Cites] JAMA. 2002 Jan 9;287(2):221-5 [11779265.001]
  • [Cites] Curr Opin Immunol. 2002 Feb;14(1):111-6 [11790540.001]
  • [Cites] Br J Ophthalmol. 2002 Feb;86(2):168-73 [11815342.001]
  • [Cites] Arch Ophthalmol. 2002 Feb;120(2):202-4 [11831924.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1251-62 [11850845.001]
  • [Cites] Can J Ophthalmol. 2002 Feb;37(1):14-9; discussion 19-20 [11865953.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]
  • [Cites] Adv Cancer Res. 2002;84:231-76 [11883529.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):429-36 [11888082.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Oncogene. 2002 Jun 6;21(25):3949-60 [12037677.001]
  • [Cites] Am J Ophthalmol. 2002 Aug;134(2):268-70 [12140037.001]
  • [Cites] J Virol. 2005 Dec;79(24):15027-37 [16306573.001]
  • [Cites] Ophthalmologe. 2005 Dec;102(12):1204-6 [15657692.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):135-40 [16236754.001]
  • [Cites] J Virol. 2006 Jan;80(2):697-709 [16378973.001]
  • [Cites] Blood. 2006 Jan 15;107(2):467-72 [16166588.001]
  • [Cites] Ophthalmologe. 2003 Oct;100(10):808-14 [14618353.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] J Pathol. 2004 Jan;202(1):23-33 [14694518.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):120-30 [14693234.001]
  • [Cites] Curr Hematol Rep. 2004 Jan;3(1):11-6 [14695844.001]
  • [Cites] Surv Ophthalmol. 2004 Jan-Feb;49(1):3-24 [14711437.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1723-32 [14724825.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] J Virol. 2004 Apr;78(8):4063-73 [15047823.001]
  • [Cites] J Clin Microbiol. 2004 Apr;42(4):1648-51 [15071020.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 21;96(8):586-94 [15100336.001]
  • [Cites] Ophthalmology. 2004 Jun;111(6):1233-7 [15177977.001]
  • [Cites] Croat Med J. 2004 Jun;45(3):328-32 [15185428.001]
  • [Cites] Eur J Haematol. 2004 Oct;73(4):258-62 [15347312.001]
  • [Cites] Klin Oczna. 2005;107(7-9):475-8 [16417001.001]
  • [Cites] Br J Haematol. 2006 Mar;132(5):651-2 [16445841.001]
  • [Cites] Jpn J Ophthalmol. 2006 Jan-Feb;50(1):7-11 [16453181.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):484-7 [16500916.001]
  • [Cites] Int J Surg Pathol. 2006 Jan;14(1):85-8 [16501843.001]
  • [Cites] Hematol Oncol. 2006 Mar;24(1):33-7 [16385613.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):365-6 [16507837.001]
  • [Cites] Virchows Arch. 2006 Mar;448(3):301-5 [16328355.001]
  • [Cites] Leuk Res. 2006 May;30(5):547-51 [16246419.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] J Infect Dis. 2006 May 1;193(9):1250-7 [16586362.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):506-16 [16323006.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3034-44 [16397126.001]
  • [Cites] Am J Gastroenterol. 2006 Apr;101(4):714-20 [16635219.001]
  • [Cites] Ann Oncol. 2006 May;17(5):769-72 [16524978.001]
  • [Cites] Cornea. 2006 May;25(4):490-2 [16670494.001]
  • [Cites] J Mol Histol. 2005 Sep;36(6-7):401-12 [16402152.001]
  • [Cites] Eur J Ophthalmol. 2006 May-Jun;16(3):473-7 [16761254.001]
  • [Cites] Am J Ophthalmol. 2006 Jun;141(6):1162-3 [16765702.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9220-5 [16751281.001]
  • [Cites] Br J Ophthalmol. 2006 Jul;90(7):819-22 [16672325.001]
  • [Cites] J Pathol. 2006 Jul;209(3):344-51 [16583361.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 8:viii15-viii23 [16801335.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1992 Jan;33(1):184-9 [1309728.001]
  • [Cites] Br J Ophthalmol. 1992 Jan;76(1):47-8 [1739692.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):632-5 [1347337.001]
  • [Cites] J Virol. 1992 Apr;66(4):2125-34 [1312623.001]
  • [Cites] Acta Ophthalmol (Copenh). 1992 Apr;70(2):248-54 [1319099.001]
  • [Cites] Adv Exp Med Biol. 1992;321:45-9; discussion 51 [1333167.001]
  • [Cites] Ophthalmology. 1993 Apr;100(4):569-73 [8386822.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] Cancer. 1994 May 1;73(9):2395-9 [8168043.001]
  • [Cites] Radiother Oncol. 1994 Mar;30(3):263-6 [7516086.001]
  • [Cites] Am J Ophthalmol. 1994 Oct 15;118(4):463-7 [7943124.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1207-11 [7525519.001]
  • [Cites] J Pathol. 1994 Sep;174(1):33-7 [7965401.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Lancet. 1995 Mar 18;345(8951):695-6 [7885126.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):761-2 [7891488.001]
  • [Cites] Br J Ophthalmol. 1995 Apr;79(4):392-3 [7742294.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Arch Ophthalmol. 1995 Aug;113(8):978 [7639671.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] Cancer Lett. 2006 Jul 28;239(1):98-102 [16143449.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):936-9 [16818858.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1055-67 [16648871.001]
  • [Cites] East Afr Med J. 2006 May;83(5):267-70 [16866221.001]
  • [Cites] Ophthalmic Epidemiol. 2006 Aug;13(4):275-9 [16877286.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):479-86 [16894296.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4491-8 [16899594.001]
  • [Cites] Leuk Res. 2006 Oct;30(10):1305-7 [16420962.001]
  • [Cites] Viral Immunol. 2006 Summer;19(3):468-80 [16987065.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82 [17018784.001]
  • [Cites] J Med Microbiol. 2006 Nov;55(Pt 11):1571-5 [17030918.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1721-2 [16760269.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11120-4 [17145854.001]
  • [Cites] Rev Med Interne. 2007 Jan;28(1):22-7 [17070619.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):170-84 [17255761.001]
  • [Cites] Clin Pharmacol Ther. 2007 Feb;81(2):259-64 [17259949.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):400-1; author reply 401-3 [17065589.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):104-8 [17325853.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):351-5 [17195763.001]
  • [Cites] Trans Am Ophthalmol Soc. 2006;104:62-70 [17471326.001]
  • [Cites] Br J Ophthalmol. 2007 Aug;91(8):1014-5 [17166894.001]
  • [Cites] Cancer Treat Res. 2007;133:185-213 [17672042.001]
  • [Cites] Leuk Res. 2007 Oct;31(10):1450-2 [17257672.001]
  • [Cites] Ophthalmology. 2007 Jan;114(1):182-6 [17198854.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Ann Dermatol Venereol. 1996;123(2):90-2 [8761758.001]
  • [Cites] Infect Immun. 1996 Nov;64(11):4872-5 [8890256.001]
  • [Cites] Nippon Ganka Gakkai Zasshi. 1996 Mar;100(3):246-52 [8900592.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Feb;83(2):259-64 [9117759.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):73-7 [9037556.001]
  • [Cites] Ophthalmology. 1995 Dec;102(12):1994-2006 [9098307.001]
  • [Cites] Am J Ophthalmol. 1997 Apr;123(4):551-2 [9124255.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):387-400 [9184771.001]
  • [Cites] Br J Ophthalmol. 1997 Apr;81(4):308-13 [9215061.001]
  • [Cites] Blood. 1997 Jul 15;90(2):776-82 [9226178.001]
  • [Cites] Aust N Z J Ophthalmol. 1997 Aug;25(3):211-5 [9296295.001]
  • [Cites] Clin Microbiol Rev. 1997 Oct;10(4):720-41 [9336670.001]
  • [Cites] J Clin Microbiol. 1999 Oct;37(10):3316-22 [10488198.001]
  • [Cites] Rev Esp Enferm Dig. 1999 Aug;91(8):541-8 [10491486.001]
  • [Cites] Am J Ophthalmol. 1999 Sep;128(3):362-4 [10511035.001]
  • [Cites] Am J Ophthalmol. 1950 Aug;33(8):1203-19 [15432557.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122(6):938-43 [15539387.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):13-8 [15309523.001]
  • [Cites] Ophthalmologe. 2004 Oct;101(10):1011-6 [15185119.001]
  • [Cites] Cytokine. 2005 Feb 21;29(4):141-52 [15652446.001]
  • [Cites] Retina. 2005 Jan;25(1):94-8 [15655452.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):290-4 [15667484.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):939-47 [15705894.001]
  • [Cites] Acta Dermatovenerol Croat. 2005;13(1):22-7 [15788143.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):773-8 [15824142.001]
  • [Cites] J Virol. 2005 Jul;79(13):8079-89 [15956553.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5067-73 [15968003.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2005 Jul;21(4):314-5 [16052151.001]
  • [Cites] Mol Carcinog. 2005 Oct;44(2):77-82 [16075467.001]
  • [Cites] Nat Rev Immunol. 2005 Oct;5(10):749-59 [16175180.001]
  • [Cites] Nippon Ganka Gakkai Zasshi. 2005 Sep;109(9):573-9 [16218435.001]
  • [Cites] Am J Ophthalmol. 2005 Oct;140(4):729-30 [16226528.001]
  • [Cites] Arch Dermatol. 2005 Nov;141(11):1429-34 [16301390.001]
  • (PMID = 18572051.001).
  • [ISSN] 0039-6257
  • [Journal-full-title] Survey of ophthalmology
  • [ISO-abbreviation] Surv Ophthalmol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 EY000222-22
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 248
  • [Other-IDs] NLM/ NIHMS58178; NLM/ PMC2507724
  •  go-up   go-down


18. Robinson JW, Brownstein S, Jordan DR, Hodge WG: Conjunctival mucoepidermoid carcinoma in a patient with ocular cicatricial pemphigoid and a review of the literature. Surv Ophthalmol; 2006 Sep-Oct;51(5):513-9
Hazardous Substances Data Bank. Ofloxacin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival mucoepidermoid carcinoma in a patient with ocular cicatricial pemphigoid and a review of the literature.
  • Invasive mucoepidermoid carcinoma of the conjunctiva of the left lower eyelid was diagnosed in an orbital exenteration specimen of a 57-year-old woman, after a biopsy of the same lesion was originally diagnosed as invasive squamous cell carcinoma.
  • The woman was undergoing mitomycin C injections for ocular cicatricial pemphigoid, diagnosed in the same eye 2 years prior to identification of the neoplasm.
  • The tumor invaded the cornea, sclera, lacrimal gland, regional small nerves, and lymphatics, but did not show intraocular involvement.
  • The original biopsy specimen was reassessed with stains for mucin and found to be mucoepidermoid carcinoma of the conjunctiva.
  • We reviewed 21 cases of mucoepidermoid carcinoma of the conjunctiva described to date in the English literature.
  • Evaluating suspected aggressive squamous cell carcinoma with special stains for mucin generally helps to identify mucoepidermoid carcinoma of the conjunctiva.
  • More extensive surgical excision than that used for squamous cell carcinoma should be implemented in the management of mucoepidermoid carcinoma of the conjunctiva to prevent recurrence.
  • [MeSH-major] Carcinoma, Mucoepidermoid / pathology. Conjunctival Neoplasms / pathology. Conjunctivitis / complications. Pemphigoid, Benign Mucous Membrane / complications
  • [MeSH-minor] Basement Membrane / pathology. Biopsy. Drug Therapy, Combination. Female. Fluorometholone / therapeutic use. Humans. Middle Aged. Mitomycin / therapeutic use. Neoplasm Invasiveness. Ofloxacin / therapeutic use


19. Molteni A, Ward WF, Ts'ao CH, Taylor J, Small W Jr, Brizio-Molteni L, Veno PA: Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr Pharm Des; 2003;9(9):751-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists.
  • Angiotensin converting enzyme (ACE) inhibitors and angiotensin II (AII) type 1 receptor antagonists have strong cytostatic properties on in vitro cultures of many normal and neoplastic cells.
  • They are effective, in particular, in reducing the growth of human lung fibroblasts, renal canine epithelial cells, bovine adrenal endothelial cells, simian T lymphocytes, and of neoplastic cell lines derived from human neuroblastomas, a ductal pancreatic carcinoma of the Syrian hamsters, human salivary glands adenocarcinomas, and two lines of human breast adenocarcinomas.
  • ACE inhibitors and AII type 1 receptor antagonists are also effective in reducing excessive vascular neoformation in a model of injury to the cornea of rats and rabbits, and in controlling the excessive angiogenesis observed in the Solt-Farber model of experimentally induced hepatoma, in methylcholantrene or radiation-induced fibrosarcomas, in radiation-induced squamous cell carcinomas and in the MA-16 viral-induced mammary carcinoma of the mouse.
  • The mitogenic effect of AII is well established and a reduction of AII synthesis may well explain cell and neoplasm delayed growth.
  • Moreover, AII regulates and enhances the activity of several growth factors including transforming growth factor B (TGFB) and smooth muscle actin (SMA); and many of these factors are reduced in tissues of animals treated with ACE inhibitors and AII type 1 receptor antagonists.
  • The ACE inhibitors containing a sulphydril (SH) or thiol radical in their moiety (Captopril and CL242817) seemed to be more effective in controlling fibrosis and the growth of some neoplastic cells than those ACE inhibitors without this thiol radical in their structure, even if the second group of these drugs show in vitro a stronger inhibitory effect on converting enzyme activity.
  • However, although these additional properties are pharmacologically relevant, the blockade of AII synthesis plays an essential role in the cytostatic activity of these two categories of drugs.
  • These observations underline that in addition to the beneficial effect of these drugs on the cardiovascular system, new potential applications are opening for their wider deployment.
  • [MeSH-minor] Animals. Humans. Neoplasms / drug therapy. Neoplasms / metabolism. Receptors, Angiotensin / physiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12570792.001).
  • [ISSN] 1381-6128
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 24652; United States / NCI NIH HHS / CA / CA 52750; United States / NCI NIH HHS / CA / CA 64239; United States / NIDDK NIH HHS / DK / DK 15612; United States / NHLBI NIH HHS / HL / HL 25106
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiotensin Receptor Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Antineoplastic Agents; 0 / Receptors, Angiotensin
  • [Number-of-references] 70
  •  go-up   go-down


20. Chen C, Louis D, Dodd T, Muecke J: Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia. Br J Ophthalmol; 2004 Jan;88(1):17-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia.
  • AIM: To report the outcome of topical mitomycin C (MMC) used as adjunctive treatment following primary excision of ocular surface squamous neoplasia (OSSN).
  • RESULT: 27 cases of OSSN received a treatment regimen of surgical excision, followed by topical MMC.
  • CONCLUSION: MMC treatment following surgical excision decreases the recurrence rate of primary ocular surface neoplasia and should be considered as adjunctive therapy in primary treatment.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Eye Neoplasms / drug therapy. Mitomycin / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Prospective Studies

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Surv Ophthalmol. 1995 May-Jun;39(6):429-50 [7660300.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):381-3 [9439364.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Curr Opin Ophthalmol. 1998 Aug;9(4):35-9 [10387466.001]
  • [Cites] Ophthalmic Surg Lasers Imaging. 2005 May-Jun;36(3):249-51 [15957484.001]
  • [Cites] Cornea. 2000 May;19(3):278-83 [10832683.001]
  • [Cites] Br J Ophthalmol. 2001 Sep;85(9):1115-9 [11520767.001]
  • [Cites] Br J Ophthalmol. 2002 Jan;86(1):31-4 [11801499.001]
  • [Cites] Cornea. 2002 Mar;21(2):189-91 [11862092.001]
  • [Cites] Clin Experiment Ophthalmol. 2002 Apr;30(2):94-8 [11886411.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [Cites] Arch Ophthalmol. 1992 Apr;110(4):525-7 [1562262.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • (PMID = 14693762.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  • [Other-IDs] NLM/ PMC1771954
  •  go-up   go-down


21. Procianoy F, Cruz AA, Baccega A, Ferraz V, Chahud F: Aggravation of eyelid and conjunctival malignancies following photodynamic therapy in DeSanctis-Cacchione syndrome. Ophthal Plast Reconstr Surg; 2006 Nov-Dec;22(6):498-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggravation of eyelid and conjunctival malignancies following photodynamic therapy in DeSanctis-Cacchione syndrome.
  • A 5-year-old girl with DeSanctis-Cacchione syndrome (a severe variant of xeroderma pigmentosum) was referred for evaluation of multiple eyelid and bulbar conjunctival squamous cell carcinomas.
  • Examination evidenced multiple vegetating lesions on the eyelid, bulbar conjunctiva, and cornea of both eyes.
  • As the lesions were considered not to be manageable by surgical excision and would have required exenteration, photodynamic therapy was performed on the patient's left eye.
  • Three months after photodynamic therapy, the patient presented with a dramatic increase in the extension of the tumors.
  • Since xeroderma pigmentosum is a DNA repair disorder, the radiation involved in photodynamic therapy probably played an iatrogenic role in the evolution of the case.
  • We believe that photodynamic therapy may be harmful to patients with DNA repair disorders.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Conjunctival Neoplasms / etiology. Eyelid Neoplasms / etiology. Photochemotherapy / adverse effects. Photosensitizing Agents / adverse effects. Ultraviolet Rays / adverse effects. Xeroderma Pigmentosum / drug therapy
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Eye Evisceration. Female. Follow-Up Studies. Humans. Severity of Illness Index. Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117119.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents
  •  go-up   go-down


22. Khong JJ, Muecke J: Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol; 2006 Jul;90(7):819-22
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.
  • AIM: To determine the complications associated with mitomycin C (MMC) in the treatment of ocular surface neoplasia.
  • Outcome measures included complications of MMC and the treatment required for these complications.
  • RESULTS: One to three 7 day cycles of topical MMC 0.04% four times a day were given to 59 eyes with localised corneal-conjunctival intraepithelial neoplasia (CIN), 19 eyes with diffuse CIN, six eyes with recurrent CIN, one eye with ocular surface squamous cell carcinoma, three eyes with primary acquired melanosis (PAM) with atypia, nine eyes with conjunctival malignant melanoma (MM), two eyes with sebaceous carcinoma with pagetoid spread, and one eye with recurrent atypical fibroxanthoma.
  • 31 (34%) cases developed an allergic reaction to MMC and 14 (14%) eyes had epiphora secondary to punctal stenosis at a mean follow up period of 26.5 months.
  • CONCLUSION: In the largest study looking at complications of topical MMC in the treatment of ocular surface neoplasia, allergic reaction and punctal stenosis are relatively common.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Drug Hypersensitivity / etiology. Eye Neoplasms / drug therapy. Mitomycin / adverse effects
  • [MeSH-minor] Adenocarcinoma, Sebaceous / drug therapy. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Female. Follow-Up Studies. Histiocytoma, Benign Fibrous / drug therapy. Humans. Lacrimal Apparatus Diseases / chemically induced. Lacrimal Duct Obstruction / chemically induced. Male. Melanoma / drug therapy. Melanosis / drug therapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Cornea. 1996 Sep;15(5):537-40 [8862932.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Br J Ophthalmol. 1998 May;82(5):476-9 [9713051.001]
  • [Cites] Am J Ophthalmol. 2005 Aug;140(2):325-7 [16086962.001]
  • [Cites] Allergy. 1997 Jun;52(6):687 [9226075.001]
  • [Cites] Contact Dermatitis. 2000 Feb;42(2):74-6 [10703627.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Ophthalmology. 2001 May;108(5):994-5 [11320034.001]
  • [Cites] Clin Experiment Ophthalmol. 2002 Apr;30(2):94-8 [11886411.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2002 Jul;18(4):285-8 [12142762.001]
  • [Cites] Ophthalmology. 2002 Nov;109(11):2129-33 [12414427.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):375-7 [12888073.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2003 May;19(3):216-24 [12918558.001]
  • [Cites] Am J Ophthalmol. 2003 Oct;136(4):746-7 [14516822.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):950-1 [15126170.001]
  • [Cites] Br J Ophthalmol. 2004 Nov;88(11):1422-4 [15489486.001]
  • [Cites] Br J Dermatol. 1990 Feb;122(2):217-24 [2138492.001]
  • [Cites] Ophthalmology. 1992 Nov;99(11):1647-54 [1454338.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [CommentIn] Br J Ophthalmol. 2006 Jul;90(7):807-9 [16782942.001]
  • (PMID = 16672325.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  • [Other-IDs] NLM/ PMC1857172
  •  go-up   go-down


23. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, Ono M: ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res; 2002 May 1;62(9):2554-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidermal growth factor receptor (EGFR) tyrosine kinase is a potential target for anticancer therapy.
  • Both ZD1839 and SU5416 [a vascular endothelial growth factor (VEGF)-receptor tyrosine kinase inhibitor] inhibited the migration of human umbilical vein endothelial cell cocultivated with EGF-stimulated cancer cells.
  • Moreover, ZD1839 almost completely blocked EGF-induced neovascularization of mice cornea, and SU5416 partially blocked neovascularization.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Endothelium, Vascular / drug effects. Enzyme Inhibitors / pharmacology. Quinazolines / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / metabolism. Cell Movement / drug effects. Cells, Cultured. Cornea / blood supply. Endothelial Growth Factors / antagonists & inhibitors. Endothelial Growth Factors / biosynthesis. Enzyme Activation / drug effects. Epidermal Growth Factor / antagonists & inhibitors. Female. Humans. Interleukin-8 / antagonists & inhibitors. Interleukin-8 / biosynthesis. Lymphokines / antagonists & inhibitors. Lymphokines / biosynthesis. Male. Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors. Mitogen-Activated Protein Kinase Kinases / metabolism. Neovascularization, Physiologic / drug effects. Tumor Cells, Cultured. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / enzymology. Vulvar Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11980649.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endothelial Growth Factors; 0 / Enzyme Inhibitors; 0 / Interleukin-8; 0 / Lymphokines; 0 / Quinazolines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; S65743JHBS / gefitinib
  •  go-up   go-down


24. Aoki S, Cho SH, Ono M, Kuwano T, Nakao S, Kuwano M, Nakagawa S, Gao JQ, Mayumi T, Shibuya M, Kobayashi M: Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells. Anticancer Drugs; 2006 Mar;17(3):269-78
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bastadin 6 also inhibited VEGF- or bFGF-induced tubular formation (0.1 micromol/l, 6 h treatment) and VEGF-induced migration (1 micromol/l, 4 h treatment) of HUVECs.
  • Moreover, bastadin 6 almost completely blocked VEGF- or bFGF-induced in vivo neovascularization in the mice corneal assay and suppressed growth of s.c. inoculated A431 solid tumor in nude mice (100 mg/kg, i.p.).
  • Bastadin 6 induced cell death of HUVECs with an apoptotic phenotype, whereas it showed no effect on the VEGF-induced auto-phosphorylation of VEGF receptors Flt-1 and KDR/Flk-1.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Apoptosis / drug effects. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / drug therapy. Endothelial Cells / drug effects. Tyrosine / analogs & derivatives
  • [MeSH-minor] Animals. Cell Growth Processes / drug effects. Cornea / blood supply. Fibroblast Growth Factor 2 / antagonists & inhibitors. Fibroblast Growth Factor 2 / pharmacology. Halogenated Diphenyl Ethers. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. NIH 3T3 Cells. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Neovascularization, Physiologic / drug effects. Porifera / chemistry. Rats. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor A / pharmacology. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520655.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Halogenated Diphenyl Ethers; 0 / Vascular Endothelial Growth Factor A; 0 / bastadin 6; 103107-01-3 / Fibroblast Growth Factor 2; 42HK56048U / Tyrosine; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


25. Teng CC, Chin KJ, Finger PT: Subconjunctival ranibizumab for squamous cell carcinoma of the conjunctiva with corneal extension. Br J Ophthalmol; 2009 Jun;93(6):837-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subconjunctival ranibizumab for squamous cell carcinoma of the conjunctiva with corneal extension.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Cornea / pathology. Humans. Middle Aged. Neoplasm Invasiveness. Ranibizumab

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19471005.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; ZL1R02VT79 / Ranibizumab
  •  go-up   go-down


26. Aldave AJ, Nguyen A: Ocular surface toxicity associated with topical interferon alpha-2b. Br J Ophthalmol; 2007 Aug;91(8):1087-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Conjunctival Neoplasms / drug therapy. Epithelium, Corneal / drug effects. Interferon-alpha / adverse effects
  • [MeSH-minor] Administration, Topical. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Humans. Male. Middle Aged. Recombinant Proteins. Treatment Outcome. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cornea. 2000 Jan;19(1):1-6 [10631999.001]
  • [Cites] Am J Ophthalmol. 2006 Oct;142(4):568-71 [17011846.001]
  • [Cites] Cornea. 2002 Jan;21(1):6-11 [11805499.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):548-52 [11874760.001]
  • [Cites] Jpn J Ophthalmol. 2002 Mar-Apr;46(2):215-7 [12062230.001]
  • [Cites] Cornea. 2004 Jan;23(1):89-92 [14701965.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1755-61 [15350333.001]
  • [Cites] Am J Ophthalmol. 1981 Apr;91(4):500-4 [6939330.001]
  • [Cites] Am J Ophthalmol. 1987 Nov 15;104(5):476-80 [3314526.001]
  • [Cites] Cornea. 1989;8(1):58-61 [2924586.001]
  • [Cites] Am J Ophthalmol. 1992 Oct 15;114(4):503-4 [1415465.001]
  • [Cites] Arch Ophthalmol. 1994 Sep;112(9):1145-6 [8085957.001]
  • [Cites] Mol Reprod Dev. 1994 Oct;39(2):226-32 [7530016.001]
  • [Cites] Am J Ophthalmol. 1998 Jan;125(1):118-9 [9437331.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Br J Ophthalmol. 1999 Jan;83(1):98-103 [10209445.001]
  • [Cites] Ophthalmology. 1999 Sep;106(9):1642-3 [10485523.001]
  • [Cites] J Ocul Pharmacol Ther. 1999 Oct;15(5):401-11 [10530701.001]
  • [Cites] Cornea. 2005 May;24(4):480-1 [15829809.001]
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • (PMID = 17638822.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  • [Other-IDs] NLM/ PMC1954794
  •  go-up   go-down


27. Esquenazi S, Fry CL, Holley E: Treatment of biopsy proved conjunctival intraepithelial neoplasia with topical interferon alfa-2b. Br J Ophthalmol; 2005 Sep;89(9):1221
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of biopsy proved conjunctival intraepithelial neoplasia with topical interferon alfa-2b.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Interferon-alpha / administration & dosage

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • [Cites] Cornea. 2002 Jan;21(1):6-11 [11805499.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Ophthalmology. 1997 Mar;104(3):485-92 [9082277.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • (PMID = 16113387.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  • [Other-IDs] NLM/ PMC1772848
  •  go-up   go-down






Advertisement